Medicare released the list of the first 10 drugs subject to price negotiations under the Inflation Reduction Act (IRA), aiming to reduce drug costs for Medicare enrollees and taxpayers.
Other featured articles
Comments to CMS on Proposed Guidance for Coverage with Evidence Development
Eleven Schaeffer fellows cosigned a comment letter to Centers for Medicaid and Medicare Services providing recommendations on the proposed Coverage with Evidence Development Guidance.
Seminar Series – Inma Hernandez
Inmaculada (Inma) Hernandez is a Professor with tenure at the University of California, San Diego (UCSD) Skaggs School of Pharmacy and Pharmaceutical Sciences. She has authored more than 100 scientific articles, including first-authored papers in JAMA, among other leading journals.
Disadvantaging Rivals: Vertical Integration in the Pharmaceutical Market
Premiums of Part D beneficiaries enrolled in a plan that is vertically integrated with a PBM increased from 30% to 80% between 2010 and 2018.
Insulin Fills by Medicare Enrollees and Out-of-Pocket Caps Under the Inflation Reduction Act
This study uses data from IQVIA’s National Prescription Audit to assess the association of the Inflation Reduction Act’s cap on cost sharing with insulin fills.
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.